A Phase 3 interventional study of Dronedarone and Placebo (for Dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 37 sites in 37 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2012-10-26.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 2nd largest by enrollment, is one of 9 that started in 2010, is one of 7 in phase 3, and was the 11th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,236 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
23 studies in Atrial Fibrillation by Sanofi: none open now, none under way, none of them phase 3. Of 23 finished, 7 (30%) have results posted.
Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2010, is one of 11 in phase 3, and was the 19th registered.
Sanofi’s Atrial Fibrillation studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 23 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objective:
This was an event-driven study where a common study end date [CSED] was to be determined by Steering Committee based on the number of events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death).
The study period per participant was variable depending on the enrollment in the study.
A final follow-up visit had to occur within 1 month after the CSED.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Permanent AF defined by the presence of all of the following criteria:
At least one of the following risk criteria:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dronedarone 400 mg twice a day until the CSED
Drug: Dronedarone
Placebo (for Dronedarone) twice a day until the CSED
Drug: Placebo (for Dronedarone)
Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)
Also known as: MULTAQ, SR33589
film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)
Overview of the Two Co-primary Outcomes
First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions \[MI\], or cardiovascular death. Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause. Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks \[TIA\], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.
Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Time to First Co-primary Outcome (Cumulative Incidence Function)
Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.
Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Time to Second Co-primary Outcome (Cumulative Incidence Function)
Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.
Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Deaths
Deaths were classified according to the primary cause of death.
Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Time to Cardiovascular Death (Cumulative Incidence Function)
Time to cardiovascular death was defined as the time from randomization to the death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.
Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Overview of Cardiovascular Events
Time frame: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
Overview of Adverse Events [AE]
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
Time frame: from first study drug intake up to 10 days after the last study drug intake
Recruitment initiated in July 2010 was discontinued on July 6, 2011 upon recommendations of the Data Monitoring Committee due to an increased number of observed cardiovascular events in the Dronedarone group. The common study end date \[CSED\] was defined as July 15, 2011. At that time 494 sites in 37 countries had enrolled at least one patient.
| Milestone | Placebo | Dronedarone |
|---|---|---|
| Started | 1617 | 1619 |
| Treated | 1610 | 1613 |
| Discontinued treatment | 171 | 342 |
| Completed | 1601 | 1591 |
| Not completed | 16 | 28 |
| Withdrew: Death | 15 | 27 |
| Withdrew: Lost to follow-up | 1 | 1 |
First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions \[MI\], or cardiovascular death. Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause. Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks \[TIA\], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.
| participants | Placebo | Dronedarone |
|---|---|---|
| First co-primary endpoint | 19 | 43 |
| Second co-primary endpoint | 67 | 127 |
Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.
| proportion of participants | Placebo | Dronedarone |
|---|---|---|
| Cumulative incidence at 14 days | 0.002 (0.000 to 0.004) | 0.009 (0.005 to 0.014) |
| Cumulative incidence at 30 days | 0.003 (0.000 to 0.006) | 0.013 (0.008 to 0.019) |
| Cumulative incidence at 90 days | 0.007 (0.003 to 0.012) | 0.021 (0.014 to 0.029) |
| Cumulative incidence at 180 days | 0.013 (0.006 to 0.021) | 0.042 (0.028 to 0.056) |
| Cumulative incidence at 270 days | 0.038 (0.012 to 0.064) | 0.045 (0.030 to 0.061) |
| Cumulative incidence at 360 days | 0.038 (0.012 to 0.064) | 0.045 (0.030 to 0.061) |
Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.
| proportion of participants | Placebo | Dronedarone |
|---|---|---|
| Cumulative incidence at 14 days | 0.005 (0.002 to 0.008) | 0.020 (0.013 to 0.027) |
| Cumulative incidence at 30 days | 0.014 (0.008 to 0.020) | 0.034 (0.025 to 0.043) |
| Cumulative incidence at 90 days | 0.033 (0.023 to 0.042) | 0.069 (0.055 to 0.083) |
| Cumulative incidence at 180 days | 0.059 (0.043 to 0.075) | 0.110 (0.089 to 0.130) |
| Cumulative incidence at 270 days | 0.099 (0.062 to 0.137) | 0.137 (0.107 to 0.167) |
| Cumulative incidence at 360 days | 0.099 (0.062 to 0.137) | 0.137 (0.107 to 0.167) |
Deaths were classified according to the primary cause of death.
| participants | Placebo | Dronedarone |
|---|---|---|
| Any death | 13 | 25 |
| - Cardiovascular death | 10 | 21 |
| --- Cardiac arrhythmic death | 4 | 13 |
Time to cardiovascular death was defined as the time from randomization to the death. Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate. 95% confidence interval was computed at each time-point using Greenwood's variance estimation.
| proportion of participants | Placebo | Dronedarone |
|---|---|---|
| Cumulative incidence at 14 days | 0.001 (0.000 to 0.003) | 0.003 (0.000 to 0.006) |
| Cumulative incidence at 30 days | 0.003 (0.000 to 0.006) | 0.005 (0.002 to 0.009) |
| Cumulative incidence at 90 days | 0.004 (0.001 to 0.007) | 0.008 (0.003 to 0.012) |
| Cumulative incidence at 180 days | 0.004 (0.001 to 0.007) | 0.022 (0.012 to 0.033) |
| Cumulative incidence at 270 days | 0.027 (0.001 to 0.052) | 0.026 (0.013 to 0.038) |
| Cumulative incidence at 360 days | 0.027 (0.001 to 0.052) | 0.026 (0.013 to 0.038) |
| participants | Placebo | Dronedarone |
|---|---|---|
| MI or unstable angina pectoris | 8 | 15 |
| - MI | 2 | 3 |
| Stroke | 10 | 23 |
| - Ischemic stroke | 9 | 18 |
| Systemic arterial embolism | 0 | 1 |
| Episode of heart failure | 55 | 115 |
| - Hospitalization due to heart failure | 24 | 43 |
| Unplanned hospitalization for cardiovascular cause | 59 | 113 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
| participants | Placebo | Dronedarone |
|---|---|---|
| Any AE | 600 | 797 |
| - Any serious AE | 77 | 113 |
| - Any AE leading to death | 0 | 4 |
| - Any AE leading to treatment discontinuation | 80 | 212 |
| - Any AE leading to hospitalization | 71 | 95 |
Collected over All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 77/1,609 (4.8%) | 38/1,609 (2.4%) |
| Dronedarone | — | 113/1,614 (7%) | 100/1,614 (6.2%) |
| Event | Placebo | Dronedarone |
|---|---|---|
| PneumoniaInfections and infestations | 9/1609 | 10/1614 |
| Renal failure acuteRenal and urinary disorders | 1/1609 | 8/1614 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 5/1609 | 6/1614 |
| Hepatic enzyme increasedInvestigations | 1/1609 | 5/1614 |
| HyponatraemiaMetabolism and nutrition disorders | 3/1609 | 0/1614 |
| GastroenteritisInfections and infestations | 0/1609 | 3/1614 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/1609 | 3/1614 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/1609 | 3/1614 |
| Renal failureRenal and urinary disorders | 2/1609 | 3/1614 |
| Urinary tract infectionInfections and infestations | 2/1609 | 2/1614 |
| Event | Placebo | Dronedarone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 38/1609 | 100/1614 |
| Age Continuous(years) | Placebo | Dronedarone | Total |
|---|---|---|---|
| Mean | 75.0 ± 5.9 | 75.0 ± 5.9 | 75.0 ± 5.9 |
| Sex: Female, Male(Participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| Female | 577 | 568 | 1145 |
| Male | 1040 | 1051 | 2091 |
| Region of Enrollment(participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| North America | 281 | 266 | 547 |
| South America | 227 | 236 | 463 |
| Western Europe | 459 | 475 | 934 |
| Eastern Europe | 495 | 488 | 983 |
| Asia | 53 | 47 | 100 |
| Rest of the word | 102 | 107 | 209 |
| Permanent atrial fibrillation [AF] history(participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| 6 months to 2 years | 490 | 498 | 988 |
| > 2 years | 1124 | 1119 | 2243 |
| Unknown | 3 | 2 | 5 |
| CHADS2 Score(participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| < 2 | 172 | 191 | 363 |
| ≥ 2 | 1444 | 1427 | 2871 |
| Unavailable | 1 | 1 | 2 |
| New York Heart Association [NYHA] class(participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| No congestive heart failure [CHF] | 535 | 512 | 1047 |
| NYHA Class I | 209 | 234 | 443 |
| NYHA Class II | 749 | 732 | 1481 |
| NYHA Class III | 124 | 141 | 265 |
The record gives a start of Jul 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronedarone